Equillium Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Equillium han disminuido a una tasa media anual de -11%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 91.4% al año.

Información clave

-11.0%

Tasa de crecimiento de los beneficios

6.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	91.4%
Rentabilidad financiera	-59.1%
Margen neto	-37.0%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

No hay actualizaciones

Recent updates

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

Mar 27

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Aug 14

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Aug 12

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Oct 08

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Mar 09

Equillium prices $30M registered direct offering

Feb 04

Equillium (EQ) Investor Presentation - Slideshow

Dec 04

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

Nov 24

FDA gives green signal to Equillium's late-stage COVID-19 trial

Oct 30

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Equillium. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:EQ Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	36	-13	14	37
30 Sep 23	43	-8	16	36
30 Jun 23	34	-18	16	36
31 Mar 23	25	-29	17	36
31 Dec 22	16	-62	17	38
30 Sep 22	0	-76	15	37
30 Jun 22	0	-72	13	35
31 Mar 22	0	-67	12	31
31 Dec 21	0	-39	11	26
30 Sep 21	0	-37	11	25
30 Jun 21	0	-34	10	23
31 Mar 21	0	-31	10	21
31 Dec 20	0	-30	10	19
30 Sep 20	0	-28	10	18
30 Jun 20	0	-28	10	18
31 Mar 20	0	-27	9	19
31 Dec 19	0	-26	9	18
30 Sep 19	0	-23	9	15
30 Jun 19	0	-22	7	12
31 Mar 19	0	-18	6	8
31 Dec 18	0	-13	4	5
30 Sep 18	0	-10	2	3

Ingresos de calidad: EQ actualmente no es rentable.

Margen de beneficios creciente: EQ actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: EQ no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 11% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de EQ en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: EQ no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: EQ tiene una rentabilidad financiera negativa (-59.08%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Equillium Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Recent updates

Price target increased by 9.5% to US$6.75

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

Consensus EPS estimates fall by 188%

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

New major risk - Share price stability

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

New minor risk - Share price stability

Price target decreased by 10% to US$6.17

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Consensus revenue estimates increase by 187%

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Consensus revenue estimates increase by 17%

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Price target decreased to US$12.00

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Price target decreased to US$12.00

Price target increased to US$14.00

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Equillium GAAP EPS of -$0.41 in-line

Insufficient new directors

Price target increased to US$13.75

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Price target decreased to US$12.50

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

Senior VP & COO notifies of intention to sell stock

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of Cd6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Chief Scientific Officer & Director exercised options and sold US$138k worth of stock

Price target decreased to US$13.75

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Consultant notifies of intention to sell stock

Equillium, Inc. Announces Positive Data Supporting the Role of Itolizumab as A Potential Treatment for Acute Graft-Versus-Host Disease

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

New 90-day high: US$9.61

Equillium, Inc. Appoints Yu (Katherine) Xu, Ph.D., as A Class II Director

Equillium prices $30M registered direct offering

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 2000 Dynamic Index

New 90-day high: US$6.80

Equillium, Inc. Appoints Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer, Effective January 11, 2021

Equillium (EQ) Investor Presentation - Slideshow

Price target lowered to US$16.25

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

Equillium Announces Positive Interim Data of Itolizumab in the First-Line Treatment of Acute Graft-Versus-Host Disease

Equillium, Inc. to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

New 90-day low: US$5.04

FDA gives green signal to Equillium's late-stage COVID-19 trial

Equillium, Inc. Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis

Equillium, Inc. Announces Executive Changes

Equillium, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Price target raised to US$18.75

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Desglose de ingresos y gastos
Beta